Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02973399
Title Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Esanex Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Weill Cornell Medical College New York New York 10065 United States Details
Wexner Medical Center, Ohio State University Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field